The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 and Female Fertility: Effects, Mechanisms, Safety and Risks The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions BPC 157: Miracle Healing Peptide or Hidden Danger? BPC 157 and TB 500: Injury Healing Peptides Jonathan L. Glashow posted on the topic LinkedIn FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times